Track topics on Twitter Track topics that are important to you
The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data
The post Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC appeared first on Pharmaceutical Business review.
Original Article: Roche’s Tecentriq, Avastin combo improves OS in unresectable HCCNEXT ARTICLE